Abzena, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (USA), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen Receptor T Cell (CAR-T) therapies for the treatment of solid and hematological cancers.
Under the agreement Abzena will humanize monoclonal antibodies using its Composite Human Antibody™ technology. This technology combines humanization and deimmunisation technologies to generate fully-humanized therapeutic antibodies devoid of CD4+ T cell epitopes.
Tmunity will use the humanised antibodies to develop CAR-T engineered products. CAR-T therapy is an innovative therapeutic form of personalised medicine in which a patient’s own T-cells are genetically modified to express an antigen recognizing CAR on the surface of the T cell. When the CAR-T encounters a cancer cell expressing the cognate antigen, the CAR-T is activated releasing cytokines that kill the cancer cell. CAR-T therapies have been successfully developed for the treatment of hematological cancers, a success that Tmunity is seeking to duplicate in solid tumors and other hematological malignancies.
The research and license agreement between Abzena and Tmunity also includes developability assessment to assess for any potential sequence liabilities that would affect quality of the product and EpiScreen™, Abzena’s ex-vivo immunogenicity assessment platform.
Headquartered at Babraham Research Campus (Cambridge, UK), Abzena provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in Europe, USA and internationally.